Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2005-08-19
2010-10-05
Gabel, Gailene R (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007100, C422S067000, C930S150000, C530S315000
Reexamination Certificate
active
07807397
ABSTRACT:
The use of copeptin as diagnostic marker for the determination of the release of vasopressin, especially in connection with disorders associated with non-physiological alterations of vasopressin release from the neurohypophysis, especially for detection and early detection, diagnosing and monitoring of the course of cardiovascular diseases, renal and pulmonary diseases as well as shock, including septic shock, sepsis and diseases/disorders of the central nervous system and neurodegenerative diseases.
REFERENCES:
patent: 2004/0253637 (2004-12-01), Buechler et al.
patent: WO 2004/006860 (2004-01-01), None
Seger et al. “The presence and in vivo biosynthesis of fragments of CPP (the C-terminal glycopeptide of the rat vasopressin precursor) in the hypothalamo-neurohypophyseal system” Peptides vol. 8 (1987), 757-762.
Harlow, E. and Lane, D., Antibodies: A Laboratory Manual (1988) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 23-24, 72-77, 555-561, 578-582, and 591-592.
Yamaji et al., “Propressophysin in Human Blood: A Possible Marker of Ectopic Vasopressin Production”, Journal of Clinical Endocrinology and Metabolism, vol. 59(3); 1984, 505-512.
Nijenhuis et al., “Familial Neurohypophysial Diabetes Insipidus in a Large Dutch Kindred: Effect of the Onset of Diabetes on Growth in Children and Cell Biological Defects of the Mutant Vasopressin Prohormone”, Journal of Clinical Endocrinology and Metabolism, vol. 86(7); 2001, 3410-3420.
Gabreëls et al., “The Vasopressin Precursor Is Not Processed in the Hypothalamus of Wolfram Syndrome Patients with Diabetes Insipidus: Evidence for the Involvement of PC2 and 7B2”, Journal of Clinical Endocrinology and Metabolism, vol. 83(11), 1998, 4026-4033.
Nijenhuis et al., “Mutations in the Vasopressin Prohormone Involved in Diabetes Insipidus Impair Endoplasmic Reticulum Export but Not Sorting”, The Journal of Biological Chemistry, vol. 274(30), 1999, 21200-21208.
International Search Report for corresponding European Patent application No. EP2005/009001, mailed Nov. 11, 2005.
G. Singh Ranger, “The Physiology and Emerging Roles of Antidiuretic Hormone”, Int. J. Clin Pract 2002, vol. 56 (10) 777-782.
Landry et al., “The Pathogenesis of Vasodilatory Shock”, The New England Journal of Medicine, vol. 345(8), Aug. 23, 2001, 588-595.
Coates et al., “Differential Cleavage of Provasopressin by the Major Molecular Forms of SPC3”, Journal of Neurochemistry, vol. 70(4), 1998, 1670-1678.
Wilson et al., “Elevated Plasma Vasopressin Concentrations During Endotoxin andE. coliShock”, Advances in Shock Research, 1981, vol. 6, 15-26.
Landry et al., “Vasopressin Deficiency Contributes to the Vasodilation of Septic Shock”, Circulation, 1997, vol. 95(5), 1122-1125.
Sharshar et al., “Depletion of Neurohypophyseal Content of Vasopressin in Septic Shock”, Crit Care Med 2002, vol. 30(3), 497-500.
Sharshar et al., “Circulating Vasopressin Levels in Septic Shock”, Crit Care Med 2003, vol. 31(6), 1752-1758.
P. Forrest, “Vasopressin and Shock”, Anaesthesia and Intensive Care, vol. 29(5), Oct. 2001, 463-472.
J.L. Vincent, “Endocrine Support in the Critically ill”, Crit Care Med 30(3), 2002, 702-703.
Holmes et al, “Science Review: Vasopressin and the cardiovascular system part 2-clinical physiology”, Crit Care 8, 2004, 15-23.
Lindner et al., “Stress Hormone Response during and after Cardiopulmonary Resuscitation”, Anaesthiology 77, 1992; 662-668.
Wenzel et al., “A Comparison of Vasopressin and Epinephrine for Out-of-Hospital Cardiopulmonary Resuscitation”, N. Engl. J. Med 350(2), 2004, 105-113.
W.G. North, “Gene Regulation of Vasopressin and Vasopressin Receptors in Cancer”, Experimental Physiology, 85 S No. 27S-40S, 2000.
Baumann et al., “Distribution, Blood Transport, and Degradation of Antidiuretic Hormone in Man”, The Journal of Clinical Investigation, vol. 57, May 1976, 1109-1116.
Smyth et al., “A New Glycopeptide in Pig, Ox and Sheep Pituitary”, Biochemical and Biophysical Research Communications, vol. 87(4), 1979, 1006-1010.
de Bree et al., “Structure-Function Relationships of the Vasopressin Prohormone Domains”, Cellular and Molecular Neurobiology, vol. 18(2) 1998, 173-191.
D.A. Holwerda, “A Glycopeptide from the Posterior Lobe of Pig Pituitaries. I. Isolation and Characterization”, Eur J. Biochem 28, 1972, 334-339.
Nagy et al., “The Glycopeptide Moiety of Vasopressin-Neurophysin Precursor is Neurohypophysial Prolactin Releasing Factor”, Biochemical and Biophysical Research Communications, vol. 151(1), 1988, 524-529.
Hyde et al., “The Vasopressin-associated Glycopeptide is not a Prolactin-Releasing Factor: Studies with Lactating Brattleboro Rats” Endocrinology, vol. 125(1), 1989, 35-40.
W.G. North, “Biosynthesis of Vasopressin and Neurophysins”, Vasopressin: Principles and Properties, New York: Plenum Press, 1987, 175-209.
Chesney et al., “Subcellular Localization of Vasopressin-like Material in Platelets”, J. Lab. Clin. Med. 1985, vol. 106 (3), 314-318.
Kluge et al., “Improved Extraction Procedure and RIA for Determination of Arginine8-Vasopressin in Plasma: Role of Premeasurement Sample Treatment and Reference Values in Children”, Clinical Chemistry vol. 45(1), 1999, 98-103.
Robertson et al., “Development and Clinical Application of a New Method for the Radioimmunoassay of Arginine Vasopressin in Human Plasma”, The Journal of Clinical Investigation, vol. 52, Sep. 1973, 2340-2352.
North et al., “Immunohistochemical Evaluation of Vasopressin Expression in Breast Fibrocystic Disease and Ductal Carcinoma In Situ (DCIS)”, Endocrine Pathology, 2003, vol. 14(3), 257-262.
North et al., “Vasopressin Gene Related Products are Markers of Human Breast Cancer”, Breast Cancer Research and Treatment, vol. 34, 1995, 229-235.
W.G. North, “Neuropeptide Production by Small Cell Carcinoma: Vasopressin and Oxytocin as Plasma Markers of Disease”, Journal of Clinical Endocrinology and Metabolism, 1991, vol. 73(6), 1316-1320.
M. Thibonnier, “Vasopressin Receptor Antagonists in Heart Failure” Current Opinion in Pharmacology 2003, vol. 3, 683-687.
Bergmann Andreas
Struck Joachim
B.R.A.H.M.S Aktiengesellschaft
Foster Christine
Gabel Gailene R
Heslin Rothenberg Farley & & Mesiti P.C.
LandOfFree
Diagnostic method for disorders using copeptin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnostic method for disorders using copeptin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnostic method for disorders using copeptin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4155166